Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion
Shaimaa S. Eissa, Michael R. Clay, Teresa Santiago, Gang Wu, Lu Wang, Barry L. Shulkin, Jennifer Picarsic, Kim E. Nichols, Patrick Campbell
Abstract
Key Points Juvenile xanthogranuloma (JXG) usually presents with lesions isolated to the skin; however, aggressive, disseminated forms also occur. Identification of a novel MRC1-PDGFRB fusion in a child with JXG guided targeted therapy with dasatinib, leading to a dramatic response.
Topics & Concepts
PDGFRBDasatinibJuvenile xanthogranulomaJuvenileMedicineInternal medicinePathologyBiologyReceptorTyrosine kinaseGeneticsGeneHistiocyteHistiocytic Disorders and TreatmentsEosinophilic Disorders and SyndromesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis